
Your 60-second money minute. Today’s topic: Businesses May Be Fighting Tariffs By Not Hiring
Loading summary
A
With a CNBC you Money minute. I'm Jessica Ettinger. Companies have been trying to handle the tariffs for nearly a year now. And it turns out some businesses have been protecting their profits by not hiring so much or even by cutting jobs.
B
So if you're going through this period of time where your input costs go up and you don't feel like you have pricing power to the consumer, the company's going to get squeezed somewhere.
A
That's former National Economic Council director in the first Trump administration, Gary Cohn on cnbc.
B
And where they've been trying to alleviate the problem is they've been doing it through human capital. So human capital has been sort of the lever that companies have been pulling to make themselves profitable.
A
Human capital, of course, is just a formal way of saying people or workers or employees.
B
And you saw it even in this last quarter's earnings announcements. We saw well over 100,000 announced layoffs in some of the bigger companies. And I think this is a trend we're going to continue to see as people fight with higher interest rate costs, higher input costs, higher commodity costs and more trade tariffs.
A
Fighting a cost increase in one spot by reducing costs in another. It's part of running a business and it may be contributing to the low hire labor market. The whole Interview is@cnbc.com I'm Jessica Ettinger, CNBC.
C
Snoring, gasping during sleep, Feeling fatigued? Wake up to Zepbound Tirzepatide, the first and only FDA approved prescription medicine for moderate to severe obstruction obstructive sleep apnea in adults with obesity. Zeb Bound is an injectable prescription medicine that may help adults with moderate to severe obstructive sleep apnea, OSA and obesity. To improve their osa, Zebbound should be used with a reduced calorie diet and increased physical activity. Zepbound is Approved as a 2.5, 5, 7.5, 10, 12.5 or 15mg injection. Zetbound contains tirzepatide and should not be used with other Tirzepatide containing products or any GLP1 receptor agonist medicines. It is not known if Zetbound is safe and effective for use in children. Do not share needles or p reuse needles. Don't take Zeb Bound if allergic to it or if you or someone in your family had medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2. Tell your doctor if you get a lump or swelling in your neck, stop Zepbound and call your doctor if you have severe stomach pain or a serious allergic reaction. Severe side effects may include inflamed pancreas or gallbladder problems. Tell your doctor if you experience vision changes, depression or suicidal thoughts before scheduled procedures with anesthesia. If you're nursing pregnant, plan to be or taking birth control pills. Taking zepbound with a sulfonylurea or insulin may cause low blood sugar. Side effects include nausea, diarrhea and vomiting, which can cause dehydration and worsen kidney problems. Talk to your doctor, call 1-800-545-979 or visit zepbound lily. Com. Zepbound and its delivery device, Base and Quickpin are registered trademarks owned or licensed by Eli Lilly and company. Its subsidiaries or affiliates.
Episode Title: Businesses May Be Fighting Tariffs By Not Hiring
Host: Jessica Ettinger (CNBC)
Date: March 30, 2026
This concise "Your Money Minute" episode explores how ongoing tariffs are affecting U.S. businesses’ hiring practices. Host Jessica Ettinger, with insights from Gary Cohn (former National Economic Council director), explains how companies are responding to rising costs by cutting back on new hires or enacting layoffs. The episode unpacks the ripple effects of trade policies and macroeconomic pressures on the labor market, providing listeners with a quick yet insightful look at a key economic issue.
Companies and Tariffs:
Profit Pressure:
Layoff Statistics:
Multiple Pressures:
Gary Cohn on what drives payroll cuts:
“Where they've been trying to alleviate the problem is they've been doing it through human capital. So human capital has been sort of the lever that companies have been pulling to make themselves profitable.” ([00:34])
Jessica Ettinger summarizing the business trade-off:
“Fighting a cost increase in one spot by reducing costs in another. It's part of running a business and it may be contributing to the low hire labor market.” ([01:07])
In this swift yet comprehensive money minute, CNBC highlights a key trend: as tariffs and costs climb, companies are pulling back on hiring, with tangible impacts on the labor market. Expert analysis from Gary Cohn provides economic context, while recent statistics show the pattern isn’t likely to end soon. Listeners are encouraged to consider not just the headlines, but the labor and business realities beneath them.
[Listen to the full interview at cnbc.com]